Novartis AG Snaps Up Cambridge Cancer Drug FirmMani
Novartis AG (ADR) (NYSE:NVS) is set to buy CoStim Pharmaceuticals Inc. to beef up its cancer immunotherapy pipeline.
The Switzerland-based company said in a statement Monday that it will acquire Cambridge, Massachusetts-based CoStim, a closely held biotechnology company for an undisclosed sum.
$35 billion annual sales
A hot field of cancer treatment known as immunotherapy may reach $35 billion in annual sales.
If you are subscribed and having an account error please clear cache and cookies if that does not work email email@example.com or click chat